In silico

Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform

Retrieved on: 
Tuesday, January 25, 2022
Chemistry, Research, Robotics, SAN, R, Biology, Clinical trial, Algorithm, GAN, Inflammatory bowel disease, Frost, RL, Achievement, Insilico Medicine, Anemia, Solution, Gans, Pharma, Frost & Sullivan, Leadership, Automation, Infection, Industry, Chronic kidney disease, Lists of World Heritage Sites, Therapy, AI, Mark (given name), Cancer, Fibrosis, Automotive Executive of the Year Award, Software, Medicine, Drug discovery, Molecule, Medical device, Management, In silico

SAN ANTONIO, Jan. 25, 2022 /PRNewswire/ -- Based on its recent analysis of the global artificial intelligence (AI)-enabled drug discovery industry, Frost & Sullivan recognizes Insilico Medicine with the 2022 Entrepreneurial Company of the Year Award in the global AI-enabled drug discovery industry.

Key Points: 
  • Pharma.AI, the end-to-end AI-enabled drug discovery and development platform of Insilico, addresses challenges that touch on chemistry, biology, and digital medicine.
  • The AI solutions and verified automated AI platform streamline research and development (R&D) efforts, remodel therapeutics discovery, and advance precision medicine.
  • In addition, these solutions accelerate research workflow, leading to rapid and cost-effective discovery and development.
  • The company is working on AI-powered robotics to create driverless drug discovery as it moves towards advanced technologies and 100% automation."

Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform

Retrieved on: 
Tuesday, January 25, 2022
Chemistry, Research, Robotics, SAN, R, Biology, Clinical trial, Algorithm, GAN, Inflammatory bowel disease, Frost, RL, Achievement, Insilico Medicine, Anemia, Solution, Gans, Pharma, Frost & Sullivan, Leadership, Automation, Infection, Industry, Chronic kidney disease, Lists of World Heritage Sites, Therapy, AI, Mark (given name), Cancer, Fibrosis, Automotive Executive of the Year Award, Software, Medicine, Drug discovery, Molecule, Medical device, Management, In silico

SAN ANTONIO, Jan. 25, 2022 /PRNewswire/ -- Based on its recent analysis of the global artificial intelligence (AI)-enabled drug discovery industry, Frost & Sullivan recognizes Insilico Medicine with the 2022 Entrepreneurial Company of the Year Award in the global AI-enabled drug discovery industry.

Key Points: 
  • Pharma.AI, the end-to-end AI-enabled drug discovery and development platform of Insilico, addresses challenges that touch on chemistry, biology, and digital medicine.
  • The AI solutions and verified automated AI platform streamline research and development (R&D) efforts, remodel therapeutics discovery, and advance precision medicine.
  • In addition, these solutions accelerate research workflow, leading to rapid and cost-effective discovery and development.
  • The company is working on AI-powered robotics to create driverless drug discovery as it moves towards advanced technologies and 100% automation."

Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 6, 2022
Biology, Fibrosis, Insilico Medicine, In silico, AI, Medicine, Intelligence, Solution, Cancer, Degenerative disease, Conference, Eastern Time Zone, Chemistry, Medical device

HONG KONGandNEW YORK, Jan. 6, 2022 /PRNewswire/ --Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • HONG KONGandNEW YORK, Jan. 6, 2022 /PRNewswire/ --Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference.
  • Alex Zhavoronkov, Founder and Chief Executive Officer of Insilico, will present on Wednesday, January 12, 2022, at 7:30 a.m. (Eastern Time).
  • Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trial analysis using next-generation AI systems.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, and autoimmune diseases.

Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 6, 2022
Biology, Fibrosis, Insilico Medicine, In silico, AI, Medicine, Intelligence, Solution, Cancer, Degenerative disease, Conference, Eastern Time Zone, Chemistry, Medical device

HONG KONGandNEW YORK, Jan. 6, 2022 /PRNewswire/ --Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • HONG KONGandNEW YORK, Jan. 6, 2022 /PRNewswire/ --Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference.
  • Alex Zhavoronkov, Founder and Chief Executive Officer of Insilico, will present on Wednesday, January 12, 2022, at 7:30 a.m. (Eastern Time).
  • Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trial analysis using next-generation AI systems.
  • Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, and autoimmune diseases.

PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation

Retrieved on: 
Thursday, September 9, 2021

Autophagy is the natural cellular degradation mechanism that removes unnecessary or dysfunctional components through a lysosome-dependent mechanism.

Key Points: 
  • Autophagy is the natural cellular degradation mechanism that removes unnecessary or dysfunctional components through a lysosome-dependent mechanism.
  • "Insilico is pleased to partner with PAQ Therapeutics to leverage our AI-driven drug discovery platforms in advancing drug R&D of ATTECs to address unmet medical needs."
  • Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and age-related diseases.
  • PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation.

PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation

Retrieved on: 
Thursday, September 9, 2021

Autophagy is the natural cellular degradation mechanism that removes unnecessary or dysfunctional components through a lysosome-dependent mechanism.

Key Points: 
  • Autophagy is the natural cellular degradation mechanism that removes unnecessary or dysfunctional components through a lysosome-dependent mechanism.
  • "Insilico is pleased to partner with PAQ Therapeutics to leverage our AI-driven drug discovery platforms in advancing drug R&D of ATTECs to address unmet medical needs."
  • Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, infectious diseases, autoimmune diseases, and age-related diseases.
  • PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation.

Enveda Biosciences Boosts its Translational Capabilities with Two Key Hires

Retrieved on: 
Monday, August 16, 2021
Technology, Research, Other Technology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Biology, Cell biology, Inflammation, Drug discovery, Doctor of Philosophy, Master of Science, Drug, Fatty liver disease, CEO, Hari, Intelligence, Senior, Science, Degenerative disease, Therapy, Machine learning, NASH, Bristol Myers Squibb, Research, Biotechnology, List of life sciences, Clinical and Translational Science, Signal transduction, Technology, Data science, Metabolomics, Engineering, Pharmacology, Insilico Medicine, Chemistry, Takeda, Industry, In silico, Founder CEO, Pharmaceutical industry

Enveda Biosciences , a leading biotechnology company harnessing the power of natures chemistry to develop next-gen small molecule therapeutics, today announced two key hires to accelerate its translational drug development efforts.

Key Points: 
  • Enveda Biosciences , a leading biotechnology company harnessing the power of natures chemistry to develop next-gen small molecule therapeutics, today announced two key hires to accelerate its translational drug development efforts.
  • Over the past two years, Enveda has built a one-of-a-kind platform for drug discovery that is now yielding a diverse range of de-risked therapeutic candidates, says Viswa Colluru, Founder & CEO of Enveda Biosciences.
  • Its the perfect time to expand our translational research team and to channel this momentum into maturing our preclinical pipeline.
  • We couldnt be more thrilled to have two proven industry pioneers, Hari and Indranil, lead this effort from within.

Quantum Drug Discovery Startup PolarisQB Announce Hiring of Pharmacologist Ian Reynolds

Retrieved on: 
Thursday, May 6, 2021
Health sciences, Life sciences, Pharmaceutical sciences, Biochemistry, Pharmacology, In silico, Drug discovery

b'DURHAM, N.C., May 6, 2021 /PRNewswire/ --Polarisqb is proud to add Dr. Ian Reynolds, a world renowned expert in pharmacology, as an advisor to the company.

Key Points: 
  • b'DURHAM, N.C., May 6, 2021 /PRNewswire/ --Polarisqb is proud to add Dr. Ian Reynolds, a world renowned expert in pharmacology, as an advisor to the company.
  • Dr. Ian Reynolds is an experienced pharmaceutical executive who has been recognized for his work in small molecule drug discovery and has helped a number ofacademic researchers translate into the world of biotech research and drug development.\nPolarisQB is proud to add Dr. Ian Reynolds, a world renowned expert in pharmacology, as an advisor to the company.\nFollowing a PhD.
  • As Dr. Reynolds stated, "The current in silico process for drug discovery requires that scientists simplify the characteristics they are testing for, to fall within the limits of classical computational parameters.
  • Dr. Reynolds expertise in pharmacology, and especially in CNS diseases, will drive forward the promise of quantum computing aided drug design.

Novadiscovery announces new clinical simulation collaboration with Takeda

Retrieved on: 
Friday, March 26, 2021
Health sciences, Pharmaceutical industry, Life sciences, Health, Clinical research, Medical statistics, Drug discovery, Modeling and simulation, Simulation, Takeda Pharmaceutical Company, Clinical trial, In silico

Lyon, France 26 March, 2021 Novadiscovery (NOVA), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a new collaboration with Takeda Pharmaceutical Company Limited (Takeda) aimed at incorporating clinical simulation technology on virtual patients into Takeda Frances access strategy.

Key Points: 
  • Lyon, France 26 March, 2021 Novadiscovery (NOVA), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a new collaboration with Takeda Pharmaceutical Company Limited (Takeda) aimed at incorporating clinical simulation technology on virtual patients into Takeda Frances access strategy.
  • Regulatory agencies are increasingly advocating for the expanded use of in silico technology to improve clinical trial efficiency and increase the probability of regulatory success.
  • Takeda, through its association with NOVA, is leading the way in incorporating disease modelling and trial simulation in virtual populations in its pipeline development programs.
  • Thierry Marquet, MD, General Manager, ad interim Takeda France, said: Our ambition is to provide faster access to innovations for patients.

Novadiscovery announces new clinical simulation collaboration with Takeda

Retrieved on: 
Friday, March 26, 2021
Health sciences, Pharmaceutical industry, Life sciences, Health, Clinical research, Medical statistics, Drug discovery, Modeling and simulation, Simulation, Takeda Pharmaceutical Company, Clinical trial, In silico

Lyon, France 26 March, 2021 Novadiscovery (NOVA), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a new collaboration with Takeda Pharmaceutical Company Limited (Takeda) aimed at incorporating clinical simulation technology on virtual patients into Takeda Frances access strategy.

Key Points: 
  • Lyon, France 26 March, 2021 Novadiscovery (NOVA), a leading health tech company offering JINKO, a best-in-class clinical trial simulation platform to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a new collaboration with Takeda Pharmaceutical Company Limited (Takeda) aimed at incorporating clinical simulation technology on virtual patients into Takeda Frances access strategy.
  • Regulatory agencies are increasingly advocating for the expanded use of in silico technology to improve clinical trial efficiency and increase the probability of regulatory success.
  • Takeda, through its association with NOVA, is leading the way in incorporating disease modelling and trial simulation in virtual populations in its pipeline development programs.
  • Thierry Marquet, MD, General Manager, ad interim Takeda France, said: Our ambition is to provide faster access to innovations for patients.